Skip to main content
Hybrigenics SA logo

Hybrigenics SA — Investor Relations & Filings

Ticker · ALHYG ISIN · FR0004153930 LEI · 9695003KQD0XMJYDX764 PA Professional, scientific and technical activities
Open in API
Filings indexed 145 across all filing types
Latest filing 2021-06-23 Declaration of Voting R…
Country FR France
Listing PA ALHYG

About Hybrigenics SA

https://www.hybrigenics-services.com/

Hybrigenics Services is a specialized provider of technologies for studying molecular interactions. Its core offering is the ULTImate Y2H™ platform, a comprehensive Yeast Two-Hybrid system used to discover protein-protein interactions, as well as interactions with DNA, RNA, and small molecules. This technology is applied to drug discovery for target deconvolution and identifying molecular glues. A second key service is the Hybribody platform, which leverages a proprietary synthetic library for the custom selection, validation, and optimization of single-domain antibodies (VHHs/Nanobodies). The company serves clients in fundamental research, pharmaceutical R&D, and agroscience.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital au 31 mai 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital au 31 mai 2021" (Information relative to the total number of voting rights and shares comprising the capital as of May 31, 2021). It explicitly states that the company is publishing this information in accordance with French commercial code and AMF regulations (Autorité des marchés financiers). The core content is a table showing the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding the total share capital and voting rights structure is typically classified under announcements related to capital structure or general regulatory disclosures. Given the options, this is a specific regulatory disclosure about the capital structure, which is closely related to share changes or general regulatory filings. Since there isn't a specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory publication, it fits best under 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA). However, since it is a routine, periodic disclosure of the existing capital structure rather than an issuance or buyback, RNS is the most appropriate general regulatory fallback, although it is very specific. Given the nature of the data (total shares/votes), it is a mandatory regulatory filing. I will classify it as RNS as it is a general regulatory announcement not covered by the more specific codes like DIV, SHA, or POS.
2021-06-23 French
Projet d'entrée d'Hybrigenics au capital de la biotech française Inoviem Scientific : comptes annuels 2020
Audit Report / Information Classification · 95% confidence The document is a press release from Hybrigenics SA concerning its investment in Inoviem Scientific. The core subject is the finalization of the audit of Inoviem Scientific's 2020 annual accounts, detailing key financial figures (revenue, EBITDA, net result) for the fiscal year ending December 31, 2020. This content strongly relates to the release of financial results for a specific period, but it is presented as a brief announcement summarizing the audited figures, not the full, comprehensive annual report (10-K) or a detailed interim report (IR). Since it announces the results of an audit and provides key financial highlights for a completed fiscal year, it aligns best with the 'Audit Report / Information' (AR) category, which covers standalone audit results, or potentially 'Earnings Release' (ER) if it were quarterly. Given the explicit mention of 'comptes annuels 2020' (2020 annual accounts) being finalized and audited, AR is the most precise fit among the options for reporting on audited annual figures outside of the full 10-K filing structure. The document length (3188 chars) suggests it is an announcement rather than the full report itself. FY 2020
2021-05-26 French
Rapport financier annuel au 31 décembre 2020
Annual Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER ANNUEL AU 31 DECEMBRE 2020' (Annual Financial Report as of December 31, 2020) for Hybrigenics SA. It contains a management report, financial statements (balance sheet, income statement), and notes. While it is an annual report, it is a standalone French 'Rapport Financier Annuel' which serves as the comprehensive yearly financial disclosure for the company. In the context of the provided categories, this aligns with the '10-K' classification, which is defined as the official yearly report covering company activity and full financial performance. FY 2020
2021-05-25 French
Signature d'un protocole pour l'entrée d'Hybrigenics au capital de la biotech française Inoviem Scientific, spécialisée dans la pharmacologie translationnelle
M&A Activity Classification · 99% confidence The document describes a definitive agreement ('protocole') for Hybrigenics to acquire a stake in another company, Inoviem Scientific. It details the structure of the acquisition, the financing mechanism (BSA-AIR), and the strategic rationale. This clearly falls under corporate actions related to investment, acquisition, or financing activities. The most appropriate category among the provided options is 'Capital/Financing Update' (CAP), as it details a significant capital transaction (investment/acquisition) and associated financing terms, or potentially 'M&A Activity' (TAR). Given the focus on acquiring a stake and the mention of financing the acquisition via a pre-announced line, CAP is a strong fit, but TAR (Merger/Takeover) is also highly relevant for an acquisition. Since the text focuses heavily on the capital structure change and the financing used for the investment, I will classify it as CAP, as it is a direct capital/financing update related to an investment, although TAR is a close second.
2021-05-17 French
Franchissement de seuils
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. It details a shareholder (DMS) crossing below the 50% threshold of capital and voting rights in HYBRIGENICS on April 30, 2021. This type of filing, which reports changes in significant share ownership levels crossing regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and specific to this regulatory event.
2021-05-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital au 30 avril 2021
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital au 30 avril 2021" (Information relative to the total number of voting rights and shares comprising the capital as of April 30, 2021). It explicitly states that it is published in accordance with French commercial code and AMF (Autorité des marchés financiers) regulations, providing the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding the total share capital and voting rights structure is typically classified as a regulatory filing or a specific announcement related to share capital structure. Given the options, it most closely aligns with an announcement concerning the capital structure or a general regulatory filing. Since it is a specific announcement about the total number of shares and voting rights, it is a mandatory disclosure. While it relates to capital, it is not a financing activity (CAP) or a share issue/repurchase (SHA/POS), but rather a periodic statement of the current structure. In many regulatory contexts, this falls under general regulatory announcements or specific capital structure disclosures. Given the provided definitions, it is a specific regulatory disclosure about the capital base. It is not a dividend notice (DIV), director dealing (DIRS), or a major shareholding notification (MRQ) which focuses on ownership changes above thresholds. It is a direct statement of the total count. This fits best under the general 'Regulatory Filings' (RNS) as a specific, mandatory disclosure that doesn't fit the other narrow categories, or potentially a very specific form of 'Share Issue/Capital Change' (SHA) if interpreted broadly, but RNS is safer for mandatory periodic updates on capital structure counts not tied to a transaction. However, since it explicitly details the total number of shares and voting rights, which is a fundamental aspect of the capital structure, and is a mandatory periodic filing, I will classify it as a general Regulatory Filing (RNS) as it is a standard regulatory disclosure not covered by the more specific transaction/event codes.
2021-05-04 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.